Mid-Trimester Blood Test and Treatment Bundle may Reduce Preterm Birth Risks: Study

Published On 2025-02-20 15:00 GMT   |   Update On 2025-02-20 15:00 GMT

According to a new research mid-trimester blood test successfully identified average-risk women at risk for preterm birth. Researchers found that a treatment bundle, including progesterone and low-dose aspirin, significantly reduced neonatal morbidity and hospital stay compared to usual care. Presented at The Pregnancy Meeting, the study showed that when paired with a three-step treatment bundle, the predictive blood test markedly improved neonatal outcomes.

Obstetric advances have had limited impact on preterm birth (PTB) rates and neonatal outcomes. We assessed outcomes in a cohort of average risk singleton pregnancies using biomarker-based PTB risk stratification, followed by interventions for those identified at higher risk. This randomized controlled trial enrolled 5,018 singleton pregnancies at 19 U.S. centers from 2020-2023. Individuals with prior PTB, short cervix, severe maternal conditions, or known genetic/fetal anomalies were excluded. We measured the ratio of maternal circulating insulin-like growth factor-binding protein 4 to sex hormone-binding globulin between 18w0d and 20w6d, with participants randomized 1:1. The control arm, blinded to test results, received usual care, while the prevention arm received test results. Prevention arm participants identified as high-risk were offered a regimen of daily vaginal progesterone, low-dose aspirin, and weekly nursing calls. Lower-risk participants in the prevention arm received usual care. Follow-up continued through delivery and neonatal discharge. The prespecified modified intent-to-treat (mITT) analysis included the control group, prevention arm low-risk participants, and high-risk participants who consented to intervention by 24 weeks, while excluding those hospitalized with COVID-19. Primary outcomes included neonatal length of stay (NNLOS) and a composite morbidity index (NMI). A planned intent-to-treat (ITT) analysis assessed multiple neonatal outcomes. Results: Baseline characteristics did not differ between arms. mITT analysis of co-primary outcomes (Table 1) showed significantly decreased NMI and NNLOS in the prevention arm. The ITT analysis displayed significant reductions in NMI (20%), NNLOS (8%), neonatal intensive care unit (NICU) length of stay (6%), and NICU admission (20%). In an average risk singleton population, a mid-trimester blood test identified pregnancies at higher PTB risk, and implementing the treatment bundle significantly reduced neonatal morbidity and hospital stay compared to usual care.


Reference:

Iriye, B. K., O'Brien, J., Ennen, C. S., Barrilleaux, P., Berkin, J., Palatnik, A., Son, M., Gyamfi-Bannerman, C., McDonald, M., Markenson, G., Sciscione, A. C., Biggio, J. R., Wolf, S., Sullivan, S., Walker, M., Shahbaba, B., & Pound, S. P. (2025, January 31). Neonatal impact of prematurity risk biomarker screening with targeted interventions: A multicenter randomized controlled trial [Conference presentation]. Aurora Ballroom, Lobby Level, Hera Women's Health, Las Vegas, NV, United States.


Keywords:

Mid-Trimester, Blood Test, Treatment, Bundle, Reduce, Preterm, Birth Risks, Iriye, B. K., O'Brien, J., Ennen, C. S., Barrilleaux, P., Berkin, J., Palatnik, A., Son, M., Gyamfi-Bannerman, C., McDonald, M., Markenson, G., Sciscione, A. C., Biggio, J. R., Wolf, S., Sullivan, S., Walker, M., Shahbaba, B., & Pound, S. P.



Tags:    
Article Source : SMFM 2025 Pregnancy Meeting

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News